8-K

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 02, 2026

Perspective Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware	001-33407	41-1458152
(State or Other Jurisdiction<br>of Incorporation)	(Commission File Number)	(IRS Employer<br>Identification No.)
c/o Perspective Therapeutics, Inc.<br><br>2401 Elliott Avenue<br><br>Suite 320
Seattle, Washington		98121
(Address of Principal Executive Offices)		(Zip Code)
Registrant’s Telephone Number, Including Area Code: (206) 676-0900
---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading<br>Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	CATX	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On February 2, 2026, Perspective Therapeutics, Inc. (the "Company") updated its corporate presentation (the "Presentation"). The Presentation contains certain estimated and projected financial information, including the Company’s estimated cash, cash equivalents and short-term investments as of December 31, 2025. The estimated and projected financial information included in the Presentation is preliminary and has not been audited, reviewed or compiled by the Company’s independent registered public accounting firm, WithumSmith+Brown, PC (“Withum”), and Withum has not performed any procedures with respect to the preliminary financial data. Accordingly, Withum does not express an opinion or any other form of assurance with respect thereto.

The Company’s actual results as of December 31, 2025 may differ from the preliminary financial data due to the completion of the Company’s closing procedures with respect to the year ended December 31, 2025, final adjustments and other developments that may arise between now and the time the financial results for the fiscal year are finalized.

Item 8.01 Other Events.

On February 2, 2026, the Company posted the Presentation to its website. A copy of the Presentation is filed herewith as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate Presentation.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PERSPECTIVE THERAPEUTICS, INC.
Date:	February 2, 2026	By:	/s/ Joel Sendek
			Joel Sendek<br>Chief Financial Officer

Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals

Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology

Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals

Proprietary Radioligand Platform Optimizes Therapeutic Index

Proprietary Pb-Based Chelator Designed for Broader and Safer Use

Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters

Imaging Optimizes Targeted Delivery to Tumor

Solid Tumors are an Attractive Market for Radiopharmaceuticals

End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway

Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio

SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need

VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2

Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs

Compelling Anti-tumor Activity with Sustained or Deepening Responses

VMT-⍺-NET: Durable Disease Control Across All Doses

Best-in-class Safety Profile1

VMT-⍺-NET: Select Adverse Events of Special Interest

VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level

Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind

VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma

Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma

Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01

Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)

VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development

FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential

PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors

Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors

PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent

Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain

Phase 1/2 Data Expected Across All 3 Clinical Programs in 2026

Abbreviations

APPENDIX

NETs Trials

VMT-⍺-NET: Baseline Patient Characteristics in ASCO-GI 2026 Data Analysis

Patient Exposure and Follow-up with [212Pb]VMT-α-NET in ASCO-GI 2026 Data Analysis

VMT-⍺-NET: Durable Disease Control Across All Doses

VMT-⍺-NET: Signal of Sustained Anti-tumor Activity

Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment

Blood Creatinine During Follow-up for All Patients Treated (n=56)

Refractory Metastatic Melanoma Trials

ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma

Perspective’s proprietary chelator has been optimized for lead-based RPTs